A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS

A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS

Antiretroviral Combinations Continue to Transform the Treatment Landscape

RELEASE DATE
03-Jul-2014
REGION
Global
Deliverable Type
Market Research
Research Code: NE48-01-00-00-00
SKU: LS00129-GL-MR_16970
AvailableYesPDF Download
$3,950.00
In stock
SKU
LS00129-GL-MR_16970
$3,950.00
DownloadLink
ENQUIRE NOW

Description

This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and global prevalence by region and country. Key market developments since Q1 2013 and key companies to watch are also included. This research service is an update of the 2013 research service titled Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS.

Table of Contents

Key Market Developments since Q1 2013

Key Findings

Evolution of Standard of Care for HIV

Key Companies to Watch

Methodology and Scope

HIV Overview

HIV Overview (continued)

Prevalence of HIV/AIDS Globally and by Region

Market Segmentation

Market Segmentation (continued)

HIV/AIDS Antiretroviral Market—Competitive Landscape ofMarketed Products

HIV/AIDS Antiretroviral Market—Competitive Landscape ofProducts in Development

HIV/AIDS Antiretroviral Market—Product Launch and Patent Expiration Timeline

HIV/AIDS Antiretroviral Market—Major Phase 3 Ongoing Trials

HIV/AIDS Antiretroviral Market—Major Phase 3 Ongoing Trials (continued)

HIV/AIDS Antiretroviral Market—Recent Pivotal Trial Results

HIV/AIDS Antiretroviral Market—Recent Pivotal Trial Results (continued)

Marketed Product Synopsis—Multi-class FDC Products

Marketed Product Synopsis—Single-class FDC Products

Marketed Product Synopsis—Single-entity Products

Marketed Product Synopsis—Single-entity Products (continued)

Marketed Product Synopsis—Single-entity Products (continued)

Marketed Product Synopsis—Single-entity Products (continued)

Marketed Product Synopsis—Single-entity Products (continued)

Marketed Product Synopsis—Single-entity Products (continued)

Marketed Product Synopsis—Single-entity Products (continued)

Pipeline Synopsis—Late-stage Development Products

Pipeline Synopsis—Late-stage Development Products (continued)

Pipeline Synopsis—Late-stage Development Products (continued)

Pipeline Synopsis—Late-stage Development Products (continued)

Pipeline Synopsis—Late-stage Development Products (continued)

Pipeline Synopsis—Late-stage Development Products (continued)

Pipeline Synopsis—Early Clinical Development Products

Pipeline Synopsis—Early Development Products

Pipeline Synopsis—Early Development Products (continued)

Pipeline Synopsis—Early Development Products (continued)

Conclusions and Recommendations

Legal Disclaimer

Decision Support Database—Prevalence of HIV Infection

Decision Support Database—Prevalence of HIV Infection (continued)

Decision Support Database—Prevalence of HIV Infection (continued)

Decision Support Database—Prevalence of HIV Infection (continued)

Decision Support Database—Prevalence of HIV Infection (continued)

Decision Support Database—Prevalence of HIV Infection (continued)

Decision Support Database—Prevalence of HIV Infection (continued)

Decision Support Database—Prevalence of HIV Infection (continued)

Decision Support Database—Prevalence of HIV Infection (continued)

Decision Support Database—Prevalence of HIV Infection (continued)

The Frost & Sullivan Story

Value Proposition: Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and global prevalence by region and country. Key market developments since Q1 2013 and key companies to watch are also included. This research service is an update of the 2013 research service titled Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS.
More Information
Deliverable Type Market Research
No Index No
Podcast No
Author Randy Budros
WIP Number NE48-01-00-00-00
Is Prebook No